appliedclinicaltrialsonline2h
New Data Emerges from Phase IIb RELIEVE UCCD Study in Ulcerative Colitis and Crohn’s Disease
Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...
PharmiWeb7h
Radiation-Induced Myelosuppression Treatment Market to Reach USD 3.5 Billion by 2028 with a 3.1% of CAGR
Radiation-Induced Myelosuppression Treatment MarketThe global Radiation-Induced Myelosuppression Treatment Market is ...
Gastric Cancer Global Market Report 2025: Impressive Global Market Trends And Leading Industry Players In Oncology
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Sanofi: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...
Managed Healthcare Executive7h
Lilly Lowers Prices of Some Zepbound Doses for Self-Pay Patients
Lowering the price of the 2.5 mg dose vial to $349 per month. Lowering the price of the 5 mg dose vial to $499 per month.